Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumor, KRAS Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableApproved For MarketingNCT05162443
What this trial is testing

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplasm
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Looking for participantsNCT05379985
What this trial is testing

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more
Revolution Medicines, Inc. 754
Testing effectiveness (Phase 2)Looking for participantsNCT07610798
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Who this might be right for
Advance Solid TumorsColon and Rectal CancerNon - Small Cell Lung Cancer NSCLC+4 more
Shenzhen Ionova Life Sciences Co., Ltd. 178
Testing effectiveness (Phase 2)Looking for participantsNCT06667544
What this trial is testing

RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

Who this might be right for
KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd. 152
Early research (Phase 1)Study completedNCT05178888
What this trial is testing

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Who this might be right for
Advanced Solid Tumor
Mirati Therapeutics Inc. 11
Early research (Phase 1)Study completedNCT04742556
What this trial is testing

Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Who this might be right for
Solid Tumors, KRAS Mutation
Boehringer Ingelheim 15
Early research (Phase 1)Looking for participantsNCT06227377
What this trial is testing

QTX3034 in Patients With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Quanta Therapeutics 250
Early research (Phase 1)Looking for participantsNCT05382559
What this trial is testing

ASP3082 in Adults With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Astellas Pharma Inc 681
Early research (Phase 1)Active Not RecruitingNCT06767046
What this trial is testing

KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

Who this might be right for
ColorectalPancreaticNon-small Cell Lung Cancer (NSCLC)
Corregene Biotechnology Co., Ltd 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT02079740
What this trial is testing

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
National Cancer Institute (NCI) 96
Early research (Phase 1)Active Not RecruitingNCT05163028
What this trial is testing

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Who this might be right for
Non Small Cell Lung CancerColorectal CancerPancreatic Cancer+4 more
HUYABIO International, LLC. 42
Testing effectiveness (Phase 2)Ended earlyNCT01562899
What this trial is testing

MEK162 and AMG 479 in Patients With Selected Solid Tumors

Who this might be right for
Metastatic Pancreatic AdenocarcinomaBRAF Mutated Melanoma
Pfizer 77
Testing effectiveness (Phase 2)Looking for participantsNCT07148128
What this trial is testing

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Who this might be right for
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal CancerAdvanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer+2 more
Auricula Biosciences Inc.
Early research (Phase 1)Not Yet RecruitingNCT07650357
What this trial is testing

CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

Who this might be right for
Advanced Solid TumorNon Small Cell Lung CancerPancreatic Carcinoma+1 more
Clasp Therapeutics, Inc. 140
Early research (Phase 1)UnknownNCT05010694
What this trial is testing

GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results

Who this might be right for
Advanced Solid Tumors Harboring With G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 18
Testing effectiveness (Phase 2)Looking for participantsNCT06385925
What this trial is testing

TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited 440
Testing effectiveness (Phase 2)Study completedNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Testing effectiveness (Phase 2)Looking for participantsNCT05288205
What this trial is testing

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Who this might be right for
KRAS P.G12CNon-small Cell Lung CancerColorectal Cancer+1 more
Allist Pharmaceuticals, Inc. 240
Testing effectiveness (Phase 2)UnknownNCT05119933
What this trial is testing

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd. 55
Very early researchLooking for participantsNCT06577532
What this trial is testing

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

Who this might be right for
Pancreatic NeoplasmsOther Solid Tumors
Ruijin Hospital 56
Next Page
110